The specter of generic competition has long loomed over copyright’s iconic drug, Viagra, raising questions about the future of similar pharmaceutical holdings. While initial periods saw significant profits, the exclusivity lapse has allowed the door for less expensive substitutes, likely reducing revenue and presenting a significant hazard for sh